You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 14, 2021

New Draft Regulations on Medical Device Management in Vietnam

Subscribe to Updates

Since 2016, the government of Vietnam has issued a number of legal documents on medical device management, including Decree No. 36/2016/ND-CP dated May 15, 2016; Decree No. 169/ND-CP dated December 31, 2018; and Decree No. 03/2020/ND-CP dated January 1, 2020; all of which are concurrently valid. In an effort to unify and streamline regulations on the management of medical devices in Vietnam, the Ministry of Health (MOH) recently developed the draft of a new decree intended to replace the three decrees above. The draft is expected to be submitted to the government for further opinion and approval in the near future.

Below are some highlights of the new draft:

1. Clinical Trials of Medical Devices

The draft adds new regulations on clinical trials of medical devices. In particular, medical device trials will include three phases, in which phases 1 and 2 need to be finished before product registration while phase 3 will be conducted after the medical devices are approved for circulation following the specific requirement from the authorities. This regulation aims to continue evaluating the safety and efficacy of medical devices after they are widely used in the community in line with their usage conditions.

The draft also specifically stipulates cases (i) requiring full-stage clinical trials, (ii) being exempted from some stages of clinical trials, and (iii) being entirely exempted from clinical trials. The full exemption is intended to be applicable to class-A medical devices and medical devices that are already approved for circulation in at least one country in the world, and have sufficient safety and efficacy data.

Also, the draft sets out provisions on the requirements and obligations of relevant entities (the owners of the medical devices that need to be clinically evaluated and entities conducting the trials); dossiers for the trial; and procedures and processes to register and approve clinical trial protocols and trial results.

2. Medical Device Circulation

The draft adds two additional cases ((c) and (d) below) that qualify for the quick registration procedure. Accordingly, under the draft, the class-B/C/D medical devices that are subject to the quick registration procedure will include:

  • Products circulated in at least two of the following countries: Japan, Canada, Australia, the U.S., an EU member country, the U.K., or Switzerland.
  • Products circulated in Vietnam prior to December 31, 2020, and satisfying both of the following conditions:
    • The product was circulated for at least three years within a period of five years before the submission date.
    • There have been no warnings about the quality or safety of the product.
  • Products granted an import license and circulated in at least two countries in the world, one of which is Japan, Canada, Australia, the U.S., an EU member country, the U.K., or Switzerland.
  • Products meeting urgent needs for national defense, security, epidemic prevention and control, and overcoming of consequences of natural disasters and catastrophes, and having no substitutes available on the market.

Further, according to the draft, the MOH’s evaluation timeline will increase – up to 120 days instead of up to 60 days under current regulations. This is to ensure the feasibility of the evaluation.

3. Importation of Ingredients for Medical Device Production

Under the draft, import licenses are not required for medical device raw materials, except for materials containing narcotic substances and precursors.

4. Medical Device Advertisement

Under the draft, the content of medical device advertising must conform with either the dossiers for declaration of applicable standards for class-A medical devices, or the registration dossiers for class-B/C/D medical devices.

In addition, advertising contents will not require approval from the authorities. Instead, the holders of medical device registration numbers or their authorized entities will be responsible for publicly declaring the intended content and form of the advertising on the Medical Equipment Management Portal before conducting the advertising; the declaration for class-A/B medical devices would be applied from July 1, 2021 while the declaration for class-C/D medical devices would be applied from July 1, 2022.

5. Transitional Regulations

The draft sets out the transition mechanisms below:

  • Import licenses for class-B/C/D medical devices granted from 2018 to 2022 will be valid until December 31, 2022.
  • The procedures for obtaining import licenses during the transition period for class-B/C/D IVD medical devices, including reagents, calibrators, and control materials, are newly stipulated; this also means that the current procedures under Circular 47/2010/TT-BYT guiding the export and import of medicines and packaging in direct contact with medicines and Circular 30/2015/TT-BYT on import of medical equipment will be abolished.

 

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

September 6, 2024
Addressing technical barriers to trade is a key priority for the Association of Southeast Asian Nations (ASEAN) as part of trade facilitation in achieving the single market and production base under the ASEAN Economic Community directive agreed in 2015. The region has been undertaking positive steps toward standard harmonization in ASEAN priority sectors, integrating and bringing about regulatory convergence by taking into account the diversities that exist in the ten ASEAN member states. Health supplements in ASEAN are under the responsibility of the Traditional Medicine and Health Supplement Product Working Group (TMHS PWG). One of the TMHS PWG’s outputs is the ASEAN Agreement on a Regulatory Framework for Health Supplements, which includes various technical requirements for health supplements that participating member states must adopt by adjusting their domestic regulations. The key ingredients of these health supplements are vitamins and minerals. While all ASEAN countries allow the use of vitamins and minerals in health supplements, the amounts allowed for use vary, depending on the nutritional requirements deemed appropriate by each country. Partly in response to these efforts for regional harmonization, there have been important changes to vitamin and mineral limits in certain ASEAN countries that are worth monitoring. Some of these are outlined below. Thailand In January 2024, the Thai Food and Drug Administration (TFDA) updated the Thai Recommended Daily Intake (Thai RDI) guidelines for the Thai population. Subsequently, the TFDA adjusted the vitamin and mineral limits in order to comply with the updated Thai RDI and to follow the ASEAN Agreement on a Regulatory Framework for Health Supplements. The TFDA’s adjustment of vitamin and mineral limits for use in food supplements came in Notification of the Ministry of Public Health (No. 448) B.E. 2566 (2023) Re: Food Supplements (No. 5), which was published in the Government Gazette on January
Read More
August 8, 2024
On July 19, 2024, Thailand’s Ministry of Public Health Notification No. 450 B.E.2567 (2024) came into effect after being published in the Government Gazette the day before. The notification introduces significant updates to the labeling requirements for prepackaged foods. This new regulation consolidates and updates Thailand’s rules for food labeling by repealing and replacing several previous notifications. The notification’s key changes and their implications for food businesses are identified below. 1. Clarified “Best Before” Definition The notification aligns the definition of “best before” with Codex standards. It now refers to the date marking the end of the period during which the food maintains its best quality under stated storage conditions. After this date, food quality may change, and the product cannot be marketed. 2. Updated Labeling Exceptions Certain foods are exempt from labeling requirements, with the latest list including: Foods sold directly to consumers by manufacturers who can provide product information. Unprocessed foods. Some fresh foods not sold directly to consumers. Prepackaged foods produced and sold for immediate consumption in food service settings. However, any of these exempt foods that have received food serial numbers must still have labels that comply with the notification. 3. Expiration Date and Best-Before Date Display The notification provides clearer language for displaying the expiration date and best-before date. If specific wording is required by other notifications, it must be followed. English equivalents are now permitted alongside Thai text. 4. Warning Displays Multiple applicable warnings can now be consolidated and displayed together, provided the complete message is included as specified. 5. Claims about Substances or Ingredients New guidelines have been established for making claims about food additives and ingredients. Claims should be factual, not deceptive, and provably not false. 6. Label Placement and Design Labels must be permanently affixed, proportionate to the packaging, and
Read More
August 8, 2024
Tilleke & Gibbins has contributed the Thailand chapter to the 2024 edition of Pharmaceutical Advertising from the International Comparative Legal Guides (ICLG) series published by Global Legal Group. This detailed guide offers an in-depth examination of pharmaceutical advertising laws and regulations in multiple jurisdictions around the globe. Each chapter of the guide, structured in a Q&A format, is organized into comprehensive sections covering various aspects of pharmaceutical advertising, including: General rules and codes of practice governing pharmaceutical advertising Required arrangements for ensuring compliance with advertising regulations Procedures for obtaining advertising approvals from regulatory authorities Penalties for non-compliance with advertising rules Guidelines for providing information prior to product authorization Requirements for advertisements directed at healthcare professionals Restrictions on the content of pharmaceutical advertisements The complete Thailand chapter is available as a PDF below. The Thailand chapter—and the full Pharmaceutical Advertising guide—are also freely available on the ICLG website.
Read More
July 31, 2024
On July 18. 2024, Vietnam’s Ministry of Health issued Circular No. 12/2024/TT-BYT promulgating National Technical Regulation QCVN 20-1:2024/BYT on the limits of contaminants for health supplements (“Circular 12”). The new national technical regulation is the very first relating to health supplements, and is expected to have a great impact on the control of health supplement quality in Vietnam. Circular 12 will take effect on August 1, 2025. Contents of Circular 12 The new circular prescribes limits of contaminants (heavy metals and microorganisms), testing samples and testing methods, management requirements, and responsibilities of entities manufacturing and trading in health supplements. Supplemented alcohol products which are declared as health supplements are notably excluded from the scope of the regulation. Transitional Provisions Health supplements which (i) have been granted a declaration registration certificate, and (ii) are manufactured before August 1, 2025, are allowed to continue to be imported, traded, and circulated until the expiry date of the product, even if it is not aligned with Circular 12, except when there is food safety warning. Declaration registration dossiers for health supplements submitted before August 1, 2025, will continue to be handled in accordance with the prevailing regulations at the time of submission. From August 1, 2025, if a health supplement with a granted declaration registration certificate has a manufacturer’s standard that does not comply with Circular 12, the party manufacturing/trading in the product must adjust the product standard to conform to Circular 12 and notify the authority of this adjustment.
Read More